RVMD insider ownership: who sold, why, and what they still hold

What stands out

Routine activity: 99.5% of sales were under disclosed plans, and no insider sold more than 1% of vested holdings.

A share of stake is shown for 0 of the 12 officers and directors who sold. 16 are left out

Left out: Alexis Borisy, Mark Goldsmith, Stephen Kelsey, Sandra Horning, Margaret Horn, Lorence Kim, Jack Anders, Elizabeth Anderson, Xiaolin Wang, Lin Wei, Flavia Borellini, Sushil Patel, Jeff Cislini, Frank Clyburn, Alan Sandler and Anthony Mancini (share of stake is being verified).

Disclosed company stock is not an insider's whole wealth.

Who sold, and how much of their stake

Officers and directors, past 12 months. Their share of stake is being verified and is not shown yet; amounts and trading plans are below.

Mark Goldsmith

President and Chief Executive Officer, Director

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$57.0MDisclosed plan

Margaret Horn

Chief Operating Officer

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$25.3MDisclosed plan

Stephen Kelsey

Senior Advisor to the Chief Executive Officer

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$21.3MDisclosed plan

Jeff Cislini

SVP & General Counsel

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$15.3MDisclosed plan

Lorence Kim

Director

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$15.0MDisclosed plan

All 12 sellers

Selling by month

Officers and directors, Oct 2025 to Oct 2026. Each sale is counted once: under a disclosed plan, else to cover taxes, else no plan disclosed.

Disclosed planTo cover taxesOne dollar scale for every month; the tallest bar is labeled

Recent activity

Past 30 days, Sep 14, 2026 to Oct 13, 2026

Sep 29, 2026Alan Sandler sold 6.3K shares ($1.3M) under a disclosed trading plan. 6K shares came in from vesting or option exercises the same day, so the holding fell by 309 net.

Who	Shares	Price	% of total stake	Total stake after	Trade date	Filed
Alan Sandler Chief Development Officer	6,309	$202.14	n/a	n/a	Sep 29, 2026	Oct 1, 2026

Sep 25, 20262 executives sold 3.9K shares ($784K) under a disclosed trading plan. 3.1K shares came in from vesting or option exercises the same day, so their combined holdings fell by 765 net.

Who	Shares	Price	% of total stake	Total stake after	Trade date	Filed
Anthony Mancini Chief Global Commercialization Officer	3,121	$200.54	n/a	n/a	Sep 25, 2026	Sep 28, 2026
Jeff Cislini SVP & General Counsel	765	$207.32	n/a	n/a	Sep 25, 2026	Sep 29, 2026

Sep 24, 2026Anthony Mancini sold 587 shares ($117K) under a disclosed trading plan.

Who	Shares	Price	% of total stake	Total stake after	Trade date	Filed
Anthony Mancini Chief Global Commercialization Officer	587	$200.00	n/a	n/a	Sep 24, 2026	Sep 28, 2026

Sep 22, 2026Elizabeth Anderson sold 10K shares ($2.0M) under a disclosed trading plan. 5.1K shares came in from vesting or option exercises the same day, so the holding fell by 5.1K net.

Who	Shares	Price	% of total stake	Total stake after	Trade date	Filed
Elizabeth Anderson Director	10,143	$193.04	n/a	n/a	Sep 22, 2026	Sep 24, 2026

Sep 18, 2026Anthony Mancini sold 1.8K shares ($347K) under a disclosed trading plan.

Who	Shares	Price	% of total stake	Total stake after	Trade date	Filed
Anthony Mancini Chief Global Commercialization Officer	1,764	$196.94	n/a	n/a	Sep 18, 2026	Sep 22, 2026

Show all 6 events

Sep 16, 20267 executives sold 34K shares ($6.8M) to cover taxes on vesting stock.

Who	Shares	Price	% of total stake	Total stake after	Trade date	Filed
Mark Goldsmith President and Chief Executive Officer, Director Also under a disclosed plan	13,988	$199.24	n/a	n/a	Sep 16, 2026	Sep 18, 2026
Stephen Kelsey Senior Advisor to the Chief Executive Officer Also under a disclosed plan	5,569	$199.24	n/a	n/a	Sep 16, 2026	Sep 18, 2026
Margaret Horn Chief Operating Officer Also under a disclosed plan	4,967	$199.24	n/a	n/a	Sep 16, 2026	Sep 18, 2026
Jack Anders Chief Financial Officer Also under a disclosed plan	4,053	$199.24	n/a	n/a	Sep 16, 2026	Sep 18, 2026
Jeff Cislini SVP & General Counsel Also under a disclosed plan	3,366	$199.24	n/a	n/a	Sep 16, 2026	Sep 18, 2026
Anthony Mancini Chief Global Commercialization Officer Also under a disclosed plan	1,774	$199.24	n/a	n/a	Sep 16, 2026	Sep 18, 2026
Alan Sandler Chief Development Officer Also under a disclosed plan	341	$199.24	n/a	n/a	Sep 16, 2026	Sep 18, 2026

"% of total stake" is the shares in an event against all the vested shares the person held that day, across every share class and holding entity, after that day's vesting. "n/a" means the person's holdings are not confirmed, or the row is a purchase. "Holdings record incomplete" means more shares were sold than the filings show the person held that day, so a percentage would be wrong.

Common questions

Is the Revolution Medicines, Inc. CEO selling stock?

Yes. Mark Goldsmith sold 450K shares ($57.0M) in the past 12 months, all of it under a trading plan disclosed in the filings.

Why are Revolution Medicines, Inc. insiders selling?

Filings rarely give a reason, and we don't guess at one. What they show is how the sales were made: 99.5% of sales by value ran under 10b5-1 trading plans disclosed in the filings and 0.5% were to cover taxes. A trading plan schedules sales in advance.

Are any Revolution Medicines, Inc. insiders buying?

No. Officers and directors reported no purchases in the past 12 months.

The evidence

Who sold12 officers and directors: amount, % of holdings, trading plan

Who sold	Amount	% of holdings	Trading plan
Mark Goldsmith President and Chief Executive Officer, Director	$57.0M 450K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Margaret Horn Chief Operating Officer	$25.3M 189K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Stephen Kelsey Senior Advisor to the Chief Executive Officer	$21.3M 112K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Jeff Cislini SVP & General Counsel	$15.3M 95K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Lorence Kim Director	$15.0M 73K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Anthony Mancini Chief Global Commercialization Officer	$9.8M 71K shares	Not confirmed share of stake is being verified. Why	93% under a disclosed plan, 7% to cover taxes
Jack Anders Chief Financial Officer	$7.1M 58K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Elizabeth Anderson Director	$2.0M 10K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Alan Sandler Chief Development Officer	$1.3M 6.7K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Sushil Patel Director	$1.0M 5.6K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Lin Wei Chief Medical Officer	$206K 2.1K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Xiaolin Wang EVP, Clinical Development	$200K 2K shares	Not confirmed share of stake is being verified. Why	Disclosed plan

The full ownership picture0 of 16 officers and directors confirmed

Vested shares across all share classes, held directly and through trusts, LLCs and family members, as reported on SEC Forms 3, 4 and 5. Unvested awards and options are never counted as owned shares.

Insider

Held Oct 13, 2025

Sold

Held Oct 13, 2026

Still held

Alexis Borisy

Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Alexis Borisy are complete.

Director

n/a

Vesting, gifts, unvested awards and holding lines for Alexis Borisy

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Alexis Borisy are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
15,955	$37.54	Jun 19, 2034	$2.7M
11,574	$37.48	Jun 26, 2035	$1.9M
3,127	$162.99	Jun 18, 2036	$130K

Estimate: options held × ($204.72 − strike price), using the most recent insider trade price on Form 4 (Sep 29, 2026), not a market close.

Mark Goldsmith

President and Chief Executive Officer, Director

n/a

−450K

n/a

Vesting, gifts, unvested awards and holding lines for Mark Goldsmith

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Mark Goldsmith are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
144,493	$0.54	Feb 11, 2028	$29.5M
344,085	$4.73	Aug 8, 2029	$68.8M
314,000	$29.80	Feb 28, 2034	$54.9M
24,464	$4.09	Mar 12, 2029	$4.9M
128,600	$102.02	Feb 28, 2036	$13.2M

Estimate: options held × ($204.72 − strike price), using the most recent insider trade price on Form 4 (Sep 29, 2026), not a market close.

Stephen Kelsey

Senior Advisor to the Chief Executive Officer

n/a

−112K

n/a

Vesting, gifts, unvested awards and holding lines for Stephen Kelsey

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Stephen Kelsey are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
6,666	$4.09	Mar 12, 2029	$1.3M
5,055	$4.73	Aug 8, 2029	$1.0M
179,900	$29.80	Feb 28, 2034	$31.5M
88,069	$40.74	Feb 28, 2035	$14.4M
47,600	$102.02	Feb 28, 2036	$4.9M

Estimate: options held × ($204.72 − strike price), using the most recent insider trade price on Form 4 (Sep 29, 2026), not a market close.

Sandra Horning

Director

n/a

Vesting, gifts, unvested awards and holding lines for Sandra Horning

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Sandra Horning are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
36,800	$20.02	Nov 8, 2033	$6.8M
10,248	$37.54	Jun 19, 2034	$1.7M
11,574	$37.48	Jun 26, 2035	$1.9M
3,127	$162.99	Jun 18, 2036	$130K

Estimate: options held × ($204.72 − strike price), using the most recent insider trade price on Form 4 (Sep 29, 2026), not a market close.

Margaret Horn

Chief Operating Officer

n/a

−189K

n/a

Vesting, gifts, unvested awards and holding lines for Margaret Horn

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Margaret Horn are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
5,941	$0.54	Feb 11, 2028	$1.2M
97,382	$4.09	Mar 12, 2029	$19.5M
114,275	$26.50	Feb 28, 2033	$20.4M
71,750	$29.80	Feb 28, 2034	$12.6M
75,075	$40.74	Feb 28, 2035	$12.3M
47,600	$102.02	Feb 28, 2036	$4.9M

Estimate: options held × ($204.72 − strike price), using the most recent insider trade price on Form 4 (Sep 29, 2026), not a market close.

Lorence Kim

Director

n/a

−73K

n/a

Vesting, gifts, unvested awards and holding lines for Lorence Kim

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Lorence Kim are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
15,955	$37.54	Jun 19, 2034	$2.7M
11,574	$37.48	Jun 26, 2035	$1.9M
3,127	$162.99	Jun 18, 2036	$130K

Estimate: options held × ($204.72 − strike price), using the most recent insider trade price on Form 4 (Sep 29, 2026), not a market close.

Jack Anders

Chief Financial Officer

n/a

−58K

n/a

Vesting, gifts, unvested awards and holding lines for Jack Anders

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Jack Anders are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
15,900	$42.45	Mar 3, 2031	$2.6M
92,400	$29.80	Feb 28, 2034	$16.2M
71,400	$40.74	Feb 28, 2035	$11.7M
45,400	$102.02	Feb 28, 2036	$4.7M
20,600	$18.56	Feb 29, 2032	$3.8M

Estimate: options held × ($204.72 − strike price), using the most recent insider trade price on Form 4 (Sep 29, 2026), not a market close.

Elizabeth Anderson

Director

n/a

−10K

n/a

Vesting, gifts, unvested awards and holding lines for Elizabeth Anderson

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Elizabeth Anderson are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
1,095	$1.12	Apr 19, 2028	$223K
15,955	$37.54	Jun 19, 2034	$2.7M
11,574	$37.48	Jun 26, 2035	$1.9M
3,127	$162.99	Jun 18, 2036	$130K

Estimate: options held × ($204.72 − strike price), using the most recent insider trade price on Form 4 (Sep 29, 2026), not a market close.

Xiaolin Wang

EVP, Clinical Development

n/a

−2K

n/a

Vesting, gifts, unvested awards and holding lines for Xiaolin Wang

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Xiaolin Wang are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
84,700	$29.80	Feb 28, 2034	$14.8M
66,500	$40.74	Feb 28, 2035	$10.9M
34,000	$102.02	Feb 28, 2036	$3.5M

Estimate: options held × ($204.72 − strike price), using the most recent insider trade price on Form 4 (Sep 29, 2026), not a market close.

Lin Wei

Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Lin Wei are complete.

Chief Medical Officer

n/a

−2.1K

n/a

Vesting, gifts, unvested awards and holding lines for Lin Wei

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Lin Wei are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
200,000	$23.85	Apr 29, 2033	$36.2M
64,400	$29.80	Feb 28, 2034	$11.3M
72,800	$40.74	Feb 28, 2035	$11.9M
34,000	$102.02	Feb 28, 2036	$3.5M

Estimate: options held × ($204.72 − strike price), using the most recent insider trade price on Form 4 (Sep 29, 2026), not a market close.

Flavia Borellini

Director

n/a

Vesting, gifts, unvested awards and holding lines for Flavia Borellini

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Flavia Borellini are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
15,955	$37.54	Jun 19, 2034	$2.7M
11,574	$37.48	Jun 26, 2035	$1.9M
3,127	$162.99	Jun 18, 2036	$130K

Estimate: options held × ($204.72 − strike price), using the most recent insider trade price on Form 4 (Sep 29, 2026), not a market close.

Sushil Patel

Director

n/a

−5.6K

n/a

Vesting, gifts, unvested awards and holding lines for Sushil Patel

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Sushil Patel are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
32,490	$16.80	Jun 15, 2032	$6.1M
13,400	$24.84	Jun 7, 2033	$2.4M
13,000	$37.54	Jun 19, 2034	$2.2M
11,574	$37.48	Jun 26, 2035	$1.9M
3,127	$162.99	Jun 18, 2036	$130K

Estimate: options held × ($204.72 − strike price), using the most recent insider trade price on Form 4 (Sep 29, 2026), not a market close.

Jeff Cislini

SVP & General Counsel

n/a

−95K

n/a

Vesting, gifts, unvested awards and holding lines for Jeff Cislini

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Jeff Cislini are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
18,000	$36.57	Jun 16, 2030	$3.0M
3,500	$21.61	Aug 31, 2032	$641K
73,500	$29.80	Feb 28, 2034	$12.9M
77,000	$40.74	Feb 28, 2035	$12.6M
32,500	$102.02	Feb 28, 2036	$3.3M

Estimate: options held × ($204.72 − strike price), using the most recent insider trade price on Form 4 (Sep 29, 2026), not a market close.

Frank Clyburn

Director

n/a

Vesting, gifts, unvested awards and holding lines for Frank Clyburn

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Frank Clyburn are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
26,540	$42.48	Aug 5, 2034	$4.3M
10,337	$37.48	Jun 26, 2035	$1.7M
3,127	$162.99	Jun 18, 2036	$130K

Estimate: options held × ($204.72 − strike price), using the most recent insider trade price on Form 4 (Sep 29, 2026), not a market close.

Alan Sandler

Chief Development Officer

n/a

−6.7K

n/a

Vesting, gifts, unvested awards and holding lines for Alan Sandler

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Alan Sandler are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
161,300	$58.84	Oct 31, 2035	$23.5M
11,700	$102.02	Feb 28, 2036	$1.2M

Estimate: options held × ($204.72 − strike price), using the most recent insider trade price on Form 4 (Sep 29, 2026), not a market close.

Anthony Mancini

Chief Global Commercialization Officer

n/a

−71K

n/a

Vesting, gifts, unvested awards and holding lines for Anthony Mancini

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Anthony Mancini are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
93,625	$33.62	Mar 31, 2035	$16.0M
26,200	$102.02	Feb 28, 2036	$2.7M

Estimate: options held × ($204.72 − strike price), using the most recent insider trade price on Form 4 (Sep 29, 2026), not a market close.

Holdings and share of stake for Revolution Medicines, Inc. are being verified, so no balances, unit counts or percentages are shown. Sales, proceeds, plan and tax status, titles and dates come straight from individual filings.

What explains the selling$155M of sales by plan status, purpose, seller and month

Officer and director open-market sales: $155M across 1,075,414 shares. Plan status and stated purpose are separate questions, and a sale can have both.

By plan status

Disclosed plan · $155M · 99.5%

0.5%

The lighter segment is sales with no plan disclosed in the filing ($720K), including tax-related sales outside a plan.

Taxes

$15.9M of sales (10.2%) cite tax obligations in their footnotes, $15.2M of them also under a plan. Example: Anthony Mancini, Sep 16, 2026

Seller	Shares sold	Proceeds	Under a disclosed plan	Share of total	Sales dates
Mark Goldsmith President and Chief Executive Officer, Director	450K	$57.0M	100%	37%	Oct 16, 2025 to Sep 16, 2026
Margaret Horn Chief Operating Officer	189K	$25.3M	100%	16%	Dec 16, 2025 to Sep 16, 2026
Stephen Kelsey Senior Advisor to the Chief Executive Officer	112K	$21.3M	100%	14%	Dec 16, 2025 to Sep 16, 2026
Jeff Cislini SVP & General Counsel	95K	$15.3M	100%	10%	Oct 17, 2025 to Sep 25, 2026
Lorence Kim Director	73K	$15.0M	100%	10%	Aug 31, 2026 to Sep 8, 2026
Anthony Mancini Chief Global Commercialization Officer	71K	$9.8M	93%	6%	Mar 25, 2026 to Sep 25, 2026
Jack Anders Chief Financial Officer	58K	$7.1M	100%	5%	Nov 11, 2025 to Sep 16, 2026
Elizabeth Anderson Director	10K	$2.0M	100%	1%	Sep 22, 2026 to Sep 22, 2026
Alan Sandler Chief Development Officer	6.7K	$1.3M	100%	0.9%	Sep 16, 2026 to Sep 29, 2026
Sushil Patel Director	5.6K	$1.0M	100%	0.7%	Jun 29, 2026 to Jun 29, 2026
Lin Wei Chief Medical Officer	2.1K	$206K	100%	0.1%	Mar 17, 2026 to Mar 17, 2026
Xiaolin Wang EVP, Clinical Development	2K	$200K	100%	0.1%	Mar 17, 2026 to Mar 17, 2026

Sales by month

Month	Sale proceeds	Disclosed plan	To cover taxes	No plan disclosed
Oct 2025	$1.7M	$1.7M	$0	$0
Nov 2025	$11.5M	$11.5M	$0	$0
Dec 2025	$2.4M	$2.4M	$0	$0
Jan 2026	$8.6M	$8.6M	$0	$0
Feb 2026	$0	$0	$0	$0
Mar 2026	$10.4M	$10.4M	$0	$0
Apr 2026	$18.4M	$18.4M	$0	$0
May 2026	$481K	$481K	$0	$0
Jun 2026	$24.0M	$23.3M	$720K	$0
Jul 2026	$0	$0	$0	$0
Aug 2026	$41.3M	$41.3M	$0	$0
Sep 2026	$36.7M	$36.7M	$0	$0
Oct 2026	$0	$0	$0	$0

Is this normal? Selling year by year5 earlier years to compare with

More than usual: about 2.5x the 5-year average. 12 insiders sold; the average is 8 a year.

12 months ending	Shares sold	Insiders who sold	Proceeds
Oct 13, 2026 Latest 12 months	1.08M	12	$155M
Oct 13, 2025 1 year earlier	392K	7	$18.9M
Oct 13, 2024 2 years earlier	464K	8	$18.6M
Oct 14, 2023 3 years earlier	231K	7	$6.8M
Oct 14, 2022 4 years earlier	12K	6	$238K
Oct 14, 2021 5 years earlier	1.04M	10	$39.1M

Open-market sales (Form 4 code S) by people who were officers or directors, in split-adjusted shares. Earlier years include people who have since left. A sale that an outside holder also reports (a family trust, a fund) is counted with outside holders in every year. Shares, not dollars, are compared, so a change in the stock price doesn't look like a change in selling. Years the filings don't fully cover are shown but left out of the average.

Known gaps and uncertainty16 officers and directors not confirmed

Holdings and share of stake are being verified. Balances, unit counts and every share-of-stake figure for Revolution Medicines, Inc. are held back until that check is finished. Sales, proceeds, plan and tax status, titles and dates come straight from individual filings and are complete.

External context: we only cite outside events when a documented connection exists. None is shown for this period.

Sources and methodology408 filings on record, 74 filed in the 12-month period, and how we read them

All 408 Forms 3, 4 and 5 on record for Revolution Medicines, Inc. (SEC CIK 1628171), filed from Feb 12, 2020 to Oct 1, 2026; 74 of them were filed in the 12 months this page covers, retrieved from SEC EDGAR on Oct 13, 2026. Prices are the ones reported in each filing, often weighted averages.

Holdings. Each holding line (a share class plus an owner, such as a trust or LLC) carries its last reported balance forward. Entities first reported during the period start at zero, so transfers between an insider's own trusts don't count as selling. Lines not reported for three years or more are listed separately and left out of totals.

Sales. A sale counts as under a 10b5-1 plan if its footnote cites one or the filing's Rule 10b5-1 box is checked, and as tax-related if its footnote cites tax obligations or sell-to-cover. Shares withheld by the company for taxes are listed separately. Sales with neither attribute are labeled "no plan disclosed".

Full methodology

Former or inactive filers (12)No filing in 18 months; last reported balances, not in any total

Name	Last filed	Last reported balance
Thilo Schroeder	Dec 9, 2024	2,581,277 shares, last reported balance as of Dec 5, 2024
Thilo Schroeder	Dec 9, 2024	5,695,193 shares, last reported balance as of Dec 5, 2024
Barbara Weber	Oct 10, 2024	8,817 shares, last reported balance as of Oct 8, 2024
Eric Schmidt	Jun 12, 2023	14,845 shares, last reported balance as of Jun 8, 2023
Neil Exter	Jun 17, 2022	46,630 shares, last reported balance as of Jun 16, 2022
Third Rock Ventures III, L.P.	Jun 10, 2022	6,041,062 shares, last reported balance as of Jun 8, 2022
Vincent Miller	Jun 24, 2021	20,133 shares, last reported balance as of Jun 22, 2021
Peter Svennilson	Apr 28, 2021	13,068 shares, last reported balance as of Apr 28, 2021
Peter Svennilson	Apr 28, 2021	4,717,267 shares, last reported balance as of Apr 28, 2021
Third Rock Ventures IV, L.P.	Feb 18, 2020	1,419,900 shares, last reported balance as of Feb 18, 2020
James Flynn	Feb 18, 2020	2,096,384 shares, last reported balance as of Feb 18, 2020
Laurence Lasky	Feb 14, 2020	No balance on record

Spotted something wrong on this page? Report an error. We check every report against the SEC filing and list what we fix in the corrections log.

Revolution Medicines, Inc. insiders sold $155M in the past 12 months. How much of their stake is that?

What stands out

Who sold, and how much of their stake

Selling by month

Recent activity

Common questions

Is the Revolution Medicines, Inc. CEO selling stock?

Why are Revolution Medicines, Inc. insiders selling?

Are any Revolution Medicines, Inc. insiders buying?

The evidence

Taxes

Sales by month